Immunome Inc. (IMNM) intrinsic value & 10-year financials
Immunome Inc. (IMNM) has a Graham intrinsic value of $106.42 per share. At $16.47 on Oct 17, 2026, the stock trades 85% below that value. Over the last 8 fiscal years revenue shrank 29.6% a year to $6.9M, with an average return on invested capital of -707.0%.
- Graham intrinsic value
- $106.42
- Share price (Oct 17, 2026)
- $16.47
- Price vs Graham value
- 85% below
- Market cap
- $1.4B
- Revenue (FY2025)
- $6.9M
- Revenue growth (8-yr CAGR)
- -29.6%
- ROIC (10-yr avg)
- -707.0%
- Free cash flow (FY2025)
- -$200.6M
IMNM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $6.9M | -$212.4M | -$2.43 | -$200.6M | -3228.8% | -1641.9% |
| FY2024 | $9.0M | -$293.0M | -$5.00 | -$118.0M | -3382.4% | -939.1% |
| FY2023 | $14.0M | -$106.8M | -$1.79 | -$8.4M | -781.4% | -485.9% |
| FY2022 | — | -$36.9M | -$1.03 | -$28.9M | — | -113.8% |
| FY2021 | — | -$24.7M | -$0.71 | -$18.3M | — | -1212.3% |
| FY2020 | -$38.0K | -$17.8M | -$1.75 | -$12.7M | 32265.8% | -589.8% |
| FY2019 | -$96.0K | -$10.4M | — | -$9.8M | 10779.2% | 34.0% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Immunome Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Immunome Inc. has historically struggled to out-earn its cost of capital, averaging just -9.7% ROIC.
Immunome Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Immunome Inc. is modeled at -29.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $106.42 per share.